등록된 논문 166건

※ 클릭시 해당 논문페이지로 이동합니다.

• KCSG PC17-01완화의료

  Discussing POLST facilitated hospice care enrollment in patients with terminal cancer.

  • 저널 Support Care Cancer. 2022 Sep;30(9):7431-7438.
  • 제1저자 안호정
  • 교신저자 고수진

• KCSG LU19-22폐암

  Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22

  • 저널 Transl Lung Cancer Res 2022;11(7):1369-1379
  • 제1저자 정현애
  • 교신저자 강진형

• KCSG BR18-23유방암분과

  Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial

  • 저널 JAMA Oncol. 2022 Sep 1;8(9):1271-1277.
  • 제1저자 안희경
  • 교신저자 정경해, 박연희

• KCSG CO09-07대장암분과

  Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07

  • 저널 J Clin Oncol. 2022 Nov 20;40(33):3868-3877.
  • 제1저자 김승태, 김선영
  • 교신저자 박영석

• KCSG HN17-11두경부식도암

  A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)

  • 저널 Clin Cancer Res. 2022 Oct 3;28(19):4240-4247.
  • 제1저자 정현애
  • 교신저자 김범석

• KCSG BR13-11유방암

  Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)

  • 저널 ESMO Open. 2021 Oct; 6(5): 100236.
  • 제1저자 김지연, 조은혜
  • 교신저자 박연희

• KCSG BR16-09유방암

  Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)

  • 저널 Cancer Res Treat. 2023 Jan;55(1):123-135.
  • 제1저자 이지은
  • 교신저자 우인숙

• KCSG LU20-11폐암

  Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)

  • 저널 Cancer . 2022 Feb 15;128(4):778-787.
  • 제1저자 김홍식, 김동완
  • 교신저자 안명주

• KCSG HN13-01두경부식도암

  Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)

  • 저널 Korean J Intern Med . 2022 Jan;37(1):190-200.
  • 제1저자 강은주, 이윤규
  • 교신저자 윤환중

• NA위암

  Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer

  • 저널 J Cancer. 2022 Jan 1;13(3):869-876.
  • 제1저자 박송이
  • 교신저자 황인규, 김희성

678910